{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"PFS was defined as the time from study enrollment (for non-randomized cohorts)/ the time from randomization (for randomized cohorts) to the first observation of progressive disease (PD) or death without documented disease progression per RECIST V1.1 criteria.","groups":[{"description":"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).","id":"OG000","title":"LY3499446 Monotherapy + Combination Drugs Phase 2"},{"description":"Docetaxel IV infusion.","id":"OG001","title":"Docetaxel Phase 2"}],"populationDescription":"Zero participants were analyzed due to early termination of study.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Progression or Death Due to Any Cause","title":"Phase 2: Progression-Free Survival (PFS) Non-Small Lung Cancer (NSCLC Cohorts)","type":"PRIMARY"}